

## Summary statistics - quantitative results

(Groups: manufacturer of instrument)

Filter: minimal size of groups n = 5

## EQA round: IFT1/18 - Immunophenotypisation

Dead line: 16.04.2018

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability												
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
<b>(253) CD 3+ T lymphocytes</b>					100							100	96	96%
Samples and groups	[%]													
<b>Sample A</b>		74,0	1,7	2,3	100	CVP	74	0,41	7%	68,8	79,2	100	99	99%
(12) Beckman Coulter		73,9	1,6	2,2	58	0						58		
(88) Becton Dickinson		74,1	1,9	2,5	39	0						39		
Other					3	0						3		
<b>Sample B</b>		74,0	1,5	2,0	100	CVP	74	0,37	7%	68,8	79,2	100	97	97%
(12) Beckman Coulter		73,9	1,4	1,9	58	0						58		
(88) Becton Dickinson		73,9	1,8	2,4	39	0						39		
Other					3	0						3		
<b>(254) CD 4+ T lymphocytes</b>					100							100	97	97%
Samples and groups	[%]													
<b>Sample A</b>		41,1	1,1	2,8	100	CVP	41,1	0,28	10%	36,9	45,3	100	98	98%
(12) Beckman Coulter		41,1	1,1	2,6	58	0						58		
(88) Becton Dickinson		41,1	1,3	3,1	39	0						39		
Other					3	0						3		
<b>Sample B</b>		42,4	1,5	3,5	100	CVP	42,4	0,36	10%	38,1	46,7	100	98	98%
(12) Beckman Coulter		42,6	1,3	3,0	58	0						58		
(88) Becton Dickinson		42,0	1,7	4,1	39	0						39		
Other					3	0						3		
<b>(255) CD 8+ T lymphocytes</b>					100							100	96	96%
Samples and groups	[%]													
<b>Sample A</b>		23,2	1,6	6,9	100	CVP	23,2	0,39	17%	19,2	27,2	100	96	96%
(12) Beckman Coulter		22,7	1,3	5,9	57	0						57		
(88) Becton Dickinson		23,8	1,8	7,4	40	0						40		
Other					3	0						3		
<b>Sample B</b>		29,0	1,3	4,6	100	CVP	29	0,33	17%	24	34	100	99	99%
(12) Beckman Coulter		28,7	1,2	4,1	57	0						57		
(88) Becton Dickinson		29,5	1,5	5,0	40	0						40		
Other					3	0						3		
<b>(256) B lymphocytes</b>					100							100	98	98%
Samples and groups	[%]													
<b>Sample A</b>		17,4	1,3	7,3	100	CVP	17,4	0,31	30%	12,1	22,7	100	98	98%
(12) Beckman Coulter		17,1	1,5	8,5	58	0						58		
(88) Becton Dickinson		17,8	1,0	5,8	39	0						39		
Other					3	0						3		
<b>Sample B</b>		9,16	0,75	8,1	100	CVP	9,16	0,18	30%	6,41	12	100	98	98%
(12) Beckman Coulter		9,07	0,79	8,7	58	0						58		
(88) Becton Dickinson		9,29	0,63	6,8	39	0						39		
Other					3	0						3		
<b>(257) NK cells</b>					100							100	92	92%
Samples and groups	[%]													
<b>Sample A</b>		7,23	1,3	18	100	CVP	7,23	0,33	36%	4,62	9,84	100	94	94%
(12) Beckman Coulter		7,40	1,4	19	57	0						57		
(88) Becton Dickinson		7,01	1,2	17	39	0						39		
Other					4	0						4		
<b>Sample B</b>		15,5	1,3	8,6	100	CVP	15,5	0,33	26%	11,4	19,6	100	96	96%
(12) Beckman Coulter		15,6	1,4	8,8	57	0						57		
(88) Becton Dickinson		15,3	1,3	8,4	39	0						39		
Other					4	0						4		

st\_kn\_p

End of report

Printed: 25.04.2018